مباشر

BioPharma DiveFDA approves AstraZeneca’s new kind of hypertension drug BioPharma DiveMerck ADC, licensed from China, hits mark in first big global trial Boston ScientificBoston Scientific buys $1.5B stake in TAVR developer MiRus - MedTech Dive Endpoints NewsRegeneron reaches $125M Parabilis deal for hard-to-catch drug targets FierceBiotechBioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal FierceBiotechAfter rare disease flop, cash-strapped Quince finds salvation in reverse merger BioWorldBiggest gainers and losers for May 11-15, 2026 Endpoints NewsDesign Therapeutics' Friedreich's ataxia data; Vincentage's obesity results from China QiagenQiagen stock (NL0012169213): QIAGEN’s U.S. diagnostics exposure stays in focus - AD HOC NEWS BioPharma DiveHøeg fired in latest FDA shakeup; 20 people die after taking Amgen drug Endpoints NewsMerck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule Endpoints NewsThe Supreme Court won't take up drugmakers' IRA cases

FierceBiotech ١٨ مايو ٢٠٢٦

Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy

Regeneron has ponied up $125 million in cash and an equity investment in Parabilis Medicines to join forces on a new type of antibody-drug conjugate that could...

Regeneron has ponied up $125 million in cash and an equity investment in Parabilis Medicines to join forces on a new type of antibody-drug conjugate that could have better luck binding to tricky target sites.